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Non-alcoholic fatty liver disease 
(NAFLD) affects almost one third of adults 
in European countries. A well-known factor 
of influence is overnutrition and insulin re-
sistance (Farrell and Larter, 2006). In con-
trast, much less attention is given to drug in-
duced steatosis (Chen et al., 2014). It is cru-
cial that steatosis inducing compounds are 
detected and excluded early in drug devel-
opment (Hewitt et al., 2007; Hengstler et al., 
2000; Vitins et al., 2014; Fisher et al., 2008; 
Rogiers et al., 1997). 
Recently, Marta Benet and colleagues 
from Barcelona and Valenica in Spain have 
published a transcriptomic signature to iden-
tify compounds with an increased risk of in-
ducing steatosis (Benet et al., 2014). Numer-
ous mechanisms can cause steatosis. Many 
steatosis-inducing drugs impair fatty acid 
beta-oxidation (FAO) by inhibiting involved 
enzymes or by blocking the transport of fatty 
acids into mitochondria.  
Moreover, compromising the mitochon-
drial respiratory chain or mitochondrial po-
tential may indirectly cause steatosis (Benet 
al., 2014; Donato and Gomez-Lechon, 2012; 
Fromenty and Pessayre, 1995). One possibil-
ity to study the potential to induce steatosis 
is to quantify the levels of neutral lipids, e.g. 
by BODIPY or oil red O staining. However, 
these techniques have been reported to be 
relatively insensitive (Benet et al., 2014). In 
their recent publication Benet and colleagues 
(2014) have established a common signature 
of three transcription factors: FOXA1, HEX 
and SREBP1C. Totally, 25 well-charact-
erized compounds were studied in HepG2 
cells. Using the aforementioned transcription 
factors as biomarkers, 92 % of the test com-
pounds were correctly classified (Benet et 
al., 2014). Currently much effort is invested 
in research on hepatotoxic mechanisms 
(Onami et al., 2014; Campos et al., 2014; 
An, 2012; Fang et al., 2012; Monteiro et al., 
2013) and in vitro systems to predict hepato-
toxicity (Godoy et al., 2015, 2013, 2009; 
Zellmer et al., 2010; Ghallab, 2014a, b).  
In this context the identification of the 
steatogenic FOXA1/HEX/SREBP1C signa-
ture by Benet and colleagues (2014) repre-
sents an important progress and should be 
included into predictive studies in future. 
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